INCYTE CORPORATION Tax Withholding Paid on Stock Awards
INCYTE CORPORATION (INCY) reported Tax Withholding Paid on Stock Awards of $6.96 million for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-04-28.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation · last filed 2026-04-28
- INCYTE CORPORATION payment, tax withholding, share-based payment arrangement for the quarter ending 2026-03-31 was $6.96M, a 26.42% decline year-over-year.
- INCYTE CORPORATION payment, tax withholding, share-based payment arrangement for the quarter ending 2025-12-31 was $16.35M, a 1745.26% increase year-over-year.
- INCYTE CORPORATION payment, tax withholding, share-based payment arrangement for the quarter ending 2025-09-30 was $50.10M, a 53.92% increase year-over-year.
- INCYTE CORPORATION payment, tax withholding, share-based payment arrangement for the quarter ending 2025-06-30 was $912.00K, a 31.98% increase year-over-year.
- INCYTE CORPORATION payment, tax withholding, share-based payment arrangement for fiscal 2025 was $76.82M, a 90.61% increase from fiscal 2024.
- INCYTE CORPORATION payment, tax withholding, share-based payment arrangement for fiscal 2024 was $40.30M, a 41.16% increase from fiscal 2023.
- INCYTE CORPORATION payment, tax withholding, share-based payment arrangement for fiscal 2023 was $28.55M, a 8.55% increase from fiscal 2022.
- INCYTE CORPORATION payment, tax withholding, share-based payment arrangement for fiscal 2022 was $26.30M, a 12.15% decline from fiscal 2021.
| Period end | Payment, Tax Withholding, Share-based Payment Arrangement 3 month | Payment, Tax Withholding, Share-based Payment Arrangement 6 month | Payment, Tax Withholding, Share-based Payment Arrangement 9 month | Payment, Tax Withholding, Share-based Payment Arrangement 12 month |
|---|---|---|---|---|
| 2026-03-31 | $6.96M 10-Q · filed 2026-04-28 | $23.30M derived: sum of 2 quarters · filed 2026-04-28 | $73.41M derived: sum of 3 quarters · filed 2026-04-28 | $74.32M derived: sum of 4 quarters · filed 2026-04-28 |
| 2025-12-31 | $16.35M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-10 | $66.45M derived: sum of 2 quarters · filed 2026-02-10 | $67.36M derived: sum of 3 quarters · filed 2026-02-10 | $76.82M 10-K · filed 2026-02-10 |
| 2025-09-30 | $50.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-28 | $51.02M derived: sum of 2 quarters · filed 2025-10-28 | $60.47M 10-Q · filed 2025-10-28 | $61.35M derived: sum of 4 quarters · filed 2026-04-28 |
| 2025-06-30 | $912.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-29 | $10.37M 10-Q · filed 2025-07-29 | $11.25M derived: sum of 3 quarters · filed 2026-04-28 | $43.80M derived: sum of 4 quarters · filed 2026-04-28 |
| 2025-03-31 | $9.45M 10-Q · filed 2026-04-28 | $10.34M derived: sum of 2 quarters · filed 2026-04-28 | $42.89M derived: sum of 3 quarters · filed 2026-04-28 | $43.58M derived: sum of 4 quarters · filed 2026-04-28 |
| 2024-12-31 | $886.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-10 | $33.44M derived: sum of 2 quarters · filed 2026-02-10 | $34.13M derived: sum of 3 quarters · filed 2026-02-10 | $40.30M 10-K · filed 2026-02-10 |
| 2024-09-30 | $32.55M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-28 | $33.24M derived: sum of 2 quarters · filed 2025-10-28 | $39.42M 10-Q · filed 2025-10-28 | $39.91M derived: sum of 4 quarters · filed 2026-02-10 |
| 2024-06-30 | $691.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-29 | $6.87M 10-Q · filed 2025-07-29 | $7.35M derived: sum of 3 quarters · filed 2026-02-10 | $31.99M derived: sum of 4 quarters · filed 2026-02-10 |
| 2024-03-31 | $6.17M 10-Q · filed 2025-04-29 | $6.66M derived: sum of 2 quarters · filed 2026-02-10 | $31.30M derived: sum of 3 quarters · filed 2026-02-10 | $31.97M derived: sum of 4 quarters · filed 2026-02-10 |
| 2023-12-31 | $489.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-10 | $25.12M derived: sum of 2 quarters · filed 2026-02-10 | $25.80M derived: sum of 3 quarters · filed 2026-02-10 | $28.55M 10-K · filed 2026-02-10 |
| 2023-09-30 | $24.63M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-29 | $25.31M derived: sum of 2 quarters · filed 2024-10-29 | $28.06M 10-Q · filed 2024-10-29 | $28.64M derived: sum of 4 quarters · filed 2025-02-10 |
| 2023-06-30 | $675.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-07-30 | $3.43M 10-Q · filed 2024-07-30 | $4.00M derived: sum of 3 quarters · filed 2025-02-10 | $22.88M derived: sum of 4 quarters · filed 2025-02-10 |
| 2023-03-31 | $2.75M 10-Q · filed 2024-04-30 | $3.33M derived: sum of 2 quarters · filed 2025-02-10 | $22.20M derived: sum of 3 quarters · filed 2025-02-10 | $26.89M derived: sum of 4 quarters · filed 2025-02-10 |
| 2022-12-31 | $577.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-10 | $19.45M derived: sum of 2 quarters · filed 2025-02-10 | $24.14M derived: sum of 3 quarters · filed 2025-02-10 | $26.30M 10-K · filed 2025-02-10 |
| 2022-09-30 | $18.87M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-10-31 | $23.56M derived: sum of 2 quarters · filed 2023-10-31 | $25.72M 10-Q · filed 2023-10-31 | $26.28M derived: sum of 4 quarters · filed 2024-02-13 |
| 2022-06-30 | $4.69M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-01 | $6.85M 10-Q · filed 2023-08-01 | $7.41M derived: sum of 3 quarters · filed 2024-02-13 | $24.17M derived: sum of 4 quarters · filed 2024-02-13 |
| 2022-03-31 | $2.16M 10-Q · filed 2023-05-02 | $2.72M derived: sum of 2 quarters · filed 2024-02-13 | $19.48M derived: sum of 3 quarters · filed 2024-02-13 | $29.75M derived: sum of 4 quarters · filed 2024-02-13 |
| 2021-12-31 | $560.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-13 | $17.32M derived: sum of 2 quarters · filed 2024-02-13 | $27.59M derived: sum of 3 quarters · filed 2024-02-13 | $29.94M 10-K · filed 2024-02-13 |
| 2021-09-30 | $16.75M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-01 | $27.03M derived: sum of 2 quarters · filed 2022-11-01 | $29.38M 10-Q · filed 2022-11-01 | |
| 2021-06-30 | $10.28M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-02 | $12.63M 10-Q · filed 2022-08-02 | ||
| 2021-03-31 | $2.35M 10-Q · filed 2022-05-03 | |||
| 2020-12-31 | $22.76M 10-K · filed 2023-02-07 | |||
| 2019-12-31 | $16.75M 10-K · filed 2022-02-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| IQVIA HOLDINGS INC. (IQV) | United States | $45.926B | 20.54 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B |